Recruiting studies: Cardiotoxicity Induced By Drug Therapy For Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Phase 2 · 10 location(s) · Rutgers, The State University of New Jersey · NCT05559164 Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT02772367 TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
NA · 1 location(s) · Norwegian University of Science and Technology · NCT06310330 Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
NA · 1 location(s) · Erasmus Medical Center · NCT06622954 Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
Phase N/A · 5 location(s) · First Hospital of China Medical University · NCT06282796 The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Phase 3 · 1 location(s) · Zhejiang Cancer Hospital · NCT06214195

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.